Positive high-level results from the pivotal Phase III MIRANDA trial showed potential first-in-class tozorakimab demonstrated a statistically significant and clinically meaningful reduction in the ...
AstraZeneca (AZN) stock is in focus as tozorakimab marks a new Phase 3 trial win in chronic obstructive pulmonary disease, a ...
AstraZeneca said on Monday its ‌experimental treatment tozorakimab showed a "meaningful reduction" in moderate-to-severe ...
(NAPSI)—Chronic obstructive pulmonary disease (COPD) affects approximately 16 million Americans and can make even simple ...
AstraZeneca’s chronic obstructive pulmonary disease (COPD) candidate has served up a third phase 3 win this year, offering ...
A new study published in the Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation shows how an innovative phone-based inhaler education program helped Medicare Advantage ...
AstraZeneca (AZN) tozorakimab achieves primary endpoint in Phase III MIRANDA trial, reducing COPD exacerbations in smokers ...
Media is asked to save the date for the American Lung Association’s Fight For Air Climb Hartford. The family-friendly event ...
Extrafine single-inhaler triple therapy with BDP/FF/GB is effective for improving health-related quality of life and lung function in COPD.
COPD without smoking? New data reveal unexpected symptoms and inflammation patterns. Read more to see what this means for ...
Among adults with COPD, those with vs. without cost-related nonadherence had worse symptom burden, health status and lung ...
Respiratory medicine has increasingly recognized the critical influence of respiratory viral infections on the development and exacerbation of chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results